Lanreotide autogel in acromegaly – a decade on

Bibliography

• Murray RD, Melmed S. The pituitary, in encyclopedia of life sciences. John Wiley & Sons, Chichester; 2006.http://www.els.net
   Google Scholar
• Yakar S, Liu JL, Stannard B, et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 1999;96(13):7324-9
   PubMed Web of Science ®Google Scholar
• Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocr Rev 1995;16(4):427-42
   PubMed Web of Science ®Google Scholar
• Melmed S. Medical progress: acromegaly. N Engl J Med 2006;355(24):2558-73
   PubMed Web of Science ®Google Scholar
• Bates AS, Van’t Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Q J Med 1993;86(5):293-9
   PubMedGoogle Scholar
• Bengtsson BA, Edén S, Ernest I, et al. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 1988;223(4):327-35
   Google Scholar
• Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998;83(8):2730-4
   PubMed Web of Science ®Google Scholar
• Dekkers OM, Biermasz NR, Pereira AM, et al. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 2008;93(1):61-7
   PubMed Web of Science ®Google Scholar
• Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 2008;159(2):89-95
   PubMed Web of Science ®Google Scholar
• Swearingen B, Barker FG II, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998;83(10):3419-26
   PubMed Web of Science ®Google Scholar
• Beauregard C, Truong U, Hardy J, Serri O. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 2003;58(1):86-91
   PubMed Web of Science ®Google Scholar
• Giustina A, Chanson P, Bronstein MD, et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 2010;95(7):3141-8
   PubMed Web of Science ®Google Scholar
• Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009;94(5):1509-17
   PubMed Web of Science ®Google Scholar
• Gittoes NJ, Sheppard MC, Johnson AP, Stewart PM. Outcome of surgery for acromegaly--the experience of a dedicated pituitary surgeon. QJM 1999;92(12):741-5
   PubMedGoogle Scholar
• Biermasz NR, van Dulken H, Roelfsema F. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. J Clin Endocrinol Metab 2000;85(12):4596-602
   Google Scholar
• Jenkins PJ, Bates P, Carson MN, et al. Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. J Clin Endocrinol Metab 2006;91(4):1239-45
   Google Scholar
• Kumar SS, Ayuk J, Murray RD. Current therapy and drug pipeline for the treatment of patients with acromegaly. Adv Ther 2009;26(4):383-403
   Google Scholar
• Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 1998;83(2):374-8
   PubMed Web of Science ®Google Scholar
• van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001;358(9295):1754-9
   PubMed Web of Science ®Google Scholar
• Buchfelder M, Schlaffer S, Droste M, et al. German Pegvisomant Observational Study. The German ACROSTUDY: past and present. Eur J Endocrinol 2009;161(Suppl 1):S3-S10
   PubMed Web of Science ®Google Scholar
• Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 2008;93(8):2957-68
   PubMed Web of Science ®Google Scholar
• Yen SS, Siler TM, DeVane GW. Effect of somatostatin in patients with acromegaly: suppression of growth hormone, prolactin, insulin and glucose levels. N Engl J Med 1974;290(17):935-8
   Google Scholar
• Christensen SE, Nerup J, Hansen AP, Lundbaek K. Effects of somatostatin on basal levels of plasma growth hormone and insulin in acromegalics: dose-response studies and attempted total growth hormone suppression. J Clin Endocrinol Metab 1976;42(5):839-45
   Google Scholar
• Plewe G, Beyer J, Krause U, et al. Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly. Lancet 1984;2(8406):782-4
   PubMed Web of Science ®Google Scholar
• Lamberts SW, Uitterlinden P, Verschoor L, et al. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med 1985;313(25):1576-80
   PubMed Web of Science ®Google Scholar
• Murray RD, Kim K, Ren SG, et al. The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. J Clin Endocrinol Metab 2004;89(6):3027-32
   PubMed Web of Science ®Google Scholar
• van der Hoek J, de Herder WW, Feelders RA, et al. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J Clin Endocrinol Metab 2004;89(2):638-45
   PubMed Web of Science ®Google Scholar
• Bruns C, Lewis I, Briner U, et al. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002;146(5):707-16
   PubMed Web of Science ®Google Scholar
• Saveanu A, Gunz G, Dufour H, et al. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab 2001;86(1):140-5
   Google Scholar
• Shimon I, Yan X, Taylor JE, et al. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest 1997;100(9):2386-92
   PubMedGoogle Scholar
• Taboada GF, Luque RM, Neto LV, et al. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur J Endocrinol 2008;158(3):295-303
   PubMed Web of Science ®Google Scholar
• Matrone C, Pivonello R, Colao A, et al. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs. Neuroendocrinology 2004;79(3):142-8
   Google Scholar
• Shimon I, Taylor JE, Dong JZ, et al. Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest 1997;99(4):789-98
   PubMed Web of Science ®Google Scholar
• Danila DC, Haidar JN, Zhang X, et al. Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors. J Clin Endocrinol Metab 2001;86(7):2976-81
   Google Scholar
• Murray RD, Kim K, Ren SG, et al. Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. J Clin Invest 2004;114(3):349-56
   PubMed Web of Science ®Google Scholar
• Valéry C, Paternostre M, Robert B, et al. Biomimetic organization: octapeptide self-assembly into nanotubes of viral capsid-like dimension. Proc Natl Acad Sci USA 2003;100(18):10258-62
   PubMed Web of Science ®Google Scholar
• Valéry C, Pouget E, Pandit A, et al. Molecular origin of the self-assembly of lanreotide into nanotubes: a mutational approach. Biophys J 2008;94(5):1782-95
   PubMed Web of Science ®Google Scholar
• Antonijoan RM, Barbanoj MJ, Cordero JA, et al. Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers. J Pharm Pharmacol 2004;56(4):471-6
   PubMed Web of Science ®Google Scholar
• Trocóniz IF, Cendrós JM, Peraire C, et al. Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects : evidence for injection interval of up to 2 months. Clin Pharmacokinet 2009;48(1):51-62
   PubMed Web of Science ®Google Scholar
• Bronstein M, Musolino N, Jallad R, et al. Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days. Clin Endocrinol (Oxf) 2005;63(5):514-19
   PubMed Web of Science ®Google Scholar
• Cendros JM, Peraire C, Trocóniz IF, Obach R. Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel. Metabolism 2005;54(10):1276-81
   PubMed Web of Science ®Google Scholar
• Garrido MJ, Cendrós JM, Ramis J, et al. Pharmacodynamic modeling of the effects of lanreotide Autogel on growth hormone and insulin-like growth factor 1. J Clin Pharmacol 2012;52(4):487-98
   PubMed Web of Science ®Google Scholar
• Caron P, Bex M, Cullen DR, et al. Group for Lanreotide Autogel Long-Term Study on Acromegaly. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 2002;87(1):99-104
   PubMed Web of Science ®Google Scholar
• Caron P, et al. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clin Endocrinol (Oxf) 2004;60(6):734-40
   PubMed Web of Science ®Google Scholar
• Schopohl J, Strasburger CJ, Caird D, et al. German Lanreotide Study Group. Efficacy and acceptability of lanreotide Autogel(R) 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR. Exp Clin Endocrinol Diabetes 2011;119(3):156-62
   PubMed Web of Science ®Google Scholar
• Caron P, Cogne M, Raingeard I, et al. Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clin Endocrinol (Oxf) 2006;64(2):209-14
   PubMed Web of Science ®Google Scholar
• Gutt B, Bidlingmaier M, Kretschmar K, et al. Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel). Exp Clin Endocrinol Diabetes 2005;113(3):139-44
   PubMed Web of Science ®Google Scholar
• Freda PU, Katznelson L, van der Lely AJ, et al. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005;90(8):4465-73
   PubMed Web of Science ®Google Scholar
• Kelly P, Maher KT, Chew SL, et al. A single-center open-label study to investigate the efficacy and safety of repeated subcutaneous injections of lanreotide Autogel in patients with acromegaly previously treated with octreotide. Endocr Pract 2010;16(2):191-7
   Google Scholar
• Tutuncu Y, Berker D, Isik S, et al. Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly. Pituitary 2012;15(3):398-404
   PubMed Web of Science ®Google Scholar
• Salvatori R, Nachtigall LB, Cook DM, et al. Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naive patients with acromegaly. Pituitary 2010;13(2):115-22
   PubMed Web of Science ®Google Scholar
• Howlett TA, Willis D, Walker G, UK Acromegaly Register Study Group (UKAR-3). Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists. Clin Endocrinol (Oxf) 2013;79(5):689-99
   PubMed Web of Science ®Google Scholar
• van Thiel SW, Romijn JA, Biermasz NR, et al. Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. Eur J Endocrinol 2004;150(4):489-95
   PubMed Web of Science ®Google Scholar
• Melmed S, Cook D, Schopohl J, et al. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary 2010;13(1):18-28
   PubMed Web of Science ®Google Scholar
• Shimatsu A, Teramoto A, Hizuka N, et al. Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism. Endocr J 2013;60(5):651-63
   PubMed Web of Science ®Google Scholar
• Attanasio R, Lanzi R, Losa M, et al. Effects of lanreotide Autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study. Endocr Pract 2008;14(7):846-55
   PubMedGoogle Scholar
• Kay R, Halsall DJ, Annamalai AK, et al. A novel mass spectrometry-based method for determining insulin-like growth factor 1: assessment in a cohort of subjects with newly diagnosed acromegaly. Clin Endocrinol (Oxf) 2013;78(3):424-30
   PubMed Web of Science ®Google Scholar
• Annamalai AK, Webb A, Kandasamy N, et al. A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. J Clin Endocrinol Metab 2013;98(3):1040-50
   PubMed Web of Science ®Google Scholar
• Lombardi G, Minuto F, Tamburrano G, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly. J Endocrinol Invest 2009;32(3):202-9
   Web of Science ®Google Scholar
• Ronchi CL, Boschetti M, Degli Uberti EC, et al. Italian Multicenter Autogel Study Group in Acromegaly. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin Endocrinol (Oxf) 2007;67(4):512-19
   PubMed Web of Science ®Google Scholar
• Colao A, Auriemma RS, Rebora A, et al. Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly. Clin Endocrinol (Oxf) 2009;71(2):237-45
   PubMed Web of Science ®Google Scholar
• Wuster C, Both S, Cordes U, et al. Primary treatment of acromegaly with high-dose lanreotide: a case series. J Med Case Rep 2010;4:85
   PubMedGoogle Scholar
• van der Lely AJ, Bernabeu I, Cap J, et al. Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. Eur J Endocrinol 2011;164(3):325-33
   PubMed Web of Science ®Google Scholar
• Hubina E, Nanzer AM, Hanson MR, et al. Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Eur J Endocrinol 2006;155(2):371-9
   Google Scholar
• Dasgupta P. Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther 2004;102(1):61-85
   PubMed Web of Science ®Google Scholar
• Mazziotti G, Giustina A. Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary 2010;13(1):60-7
   PubMed Web of Science ®Google Scholar
• Caron PJ, Bevan JS, Petersenn S, et al. Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J Clin Endocrinol Metab 2014;99(4):1282-90
   PubMed Web of Science ®Google Scholar
• Auriemma RS, Galdiero M, Grasso LF, et al. Complete disappearance of a GH-secreting pituitary macroadenoma in a patient with acromegaly: effect of treatment with lanreotide Autogel and consequence of treatment withdrawal. Eur J Endocrinol 2010;162(5):993-9
   PubMed Web of Science ®Google Scholar
• Chanson P, Borson-Chazot F, Kuhn JM, et al. Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clin Endocrinol (Oxf) 2008;69(2):299-305
   PubMed Web of Science ®Google Scholar
• Salvatori R, Woodmansee WW, Molitch M, et al. Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry. Pituitary 2014;17(1):13-21
   Google Scholar
• Steffin B, Gutt B, Bidlingmaier M, et al. Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly. Eur J Endocrinol 2006;155(1):73-8
   PubMed Web of Science ®Google Scholar
• Alexopoulou O, Abrams P, Verhelst J, et al. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol 2004;151(3):317-24
   PubMed Web of Science ®Google Scholar
• Adelman DT, Burgess A, Davies PR. Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study. Med Devices (Auckl) 2012;5:103-9
   Google Scholar
• Andries M, Glintborg D, Kvistborg A, et al. A 12-month randomized crossover study on the effects of Lanreotide Autogel and Octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. Clin Endocrinol (Oxf) 2008;68(3):473-80
   PubMed Web of Science ®Google Scholar
• Abrams P, Alexopoulou O, Abs R, et al. Optimalization and cost management of lanreotide-Autogel therapy in acromegaly. Eur J Endocrinol 2007;157(5):571-7
   PubMed Web of Science ®Google Scholar
• Bevan JS, Newell-Price J, Wass JA, et al. Home administration of lanreotide Autogel((R)) by patients with acromegaly, or their partners, is safe and effective. Clin Endocrinol (Oxf) 2008;68(3):343-9
   Web of Science ®Google Scholar
• Marty R, Roze S, Kurth H. Decision-tree model for health economic comparison of two long-acting somatostatin receptor ligand devices in France, Germany, and the UK. Med Devices (Auckl) 2012;5:39-44
   PubMedGoogle Scholar
• Tuvia S, Atsmon J, Teichman SL, et al. Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J Clin Endocrinol Metab 2012;97(7):2362-9
   PubMed Web of Science ®Google Scholar
• Jaquet P, Gunz G, Saveanu A, et al. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur J Endocrinol 2005;153(1):135-41
   PubMed Web of Science ®Google Scholar
• Ashwell SG, Bevan JS, Edwards OM, et al. The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. Eur J Endocrinol 2004;150(4):473-80
   PubMed Web of Science ®Google Scholar